SynthesisBMC musculoskeletal disorders2025
Prognostic assessment of sarcopenia in patients with fractures: a systematic review and meta-analysis.
Synthesis in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Peri-operative nutrition in femoral neck fracture arthroplasty: a pragmatic framework to mitigate dual-hit catabolism and improve outcomes.Orthopedic reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, the prevalence of sarcopenia is on the rise. Sarcopenia may significantly affect the prognosis of fracture patients by increasing postoperative complications, diminishing quality of life, and raising mortality rates. This studyaims to investigate the impact of sarcopenia on the prognosis of fractures.
methodsA systematic search was carried out in PubMed, Embase, Cochrane Library, and Web of Science using the keywords "sarcopenia" and "fracture" from the inception of each database to January 14, 2025. The logarithm and its standard error of the odds ratio (OR) were calculated to assess the effect size. Sensitivity analysis was conducted using a one-by-one exclusion approach. Publication bias was evaluated through funnel plots, Egger's test, Begg's test, and the trim and fill method.
resultsOur pooled analysis of data from 30 studies, comprising 32 datasets, demonstrated that sarcopenia significantly elevated the risk of poor prognosis in fracture patients (OR 1.51, 95% CI 1.24-1.85), particularly, the risk of refracture (OR 1.66, 95% CI 1.36-2.03). In hip fractures, sarcopenia similarly increased the risk of poor prognosis (OR 1.43, 95% CI 1.17-1.76), refracture (OR 1.54, 95% CI 1.21-1.96) and poor functional recovery (OR 2.13, 95% CI 1.41-3.21).
conclusionSarcopenia plays a crucial role as a risk factor for poor prognosis in patients with fractures, including both an elevated risk of mortality, refracture and poor functional recovery. This necessitates that clinical workers place greater emphasis on the identification and diagnosis of sarcopenia in practice, deliver enhanced clinical care tailored to fracture patients, conduct more prospective studies, and advocate for the global standardization of sarcopenia diagnostic criteria in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.